Korean J Hematol 1997; 32(1):

Published online March 31, 1997

© The Korean Society of Hematology

만성 골수성 백혈병에서의 CD34 단클론항체 염색의 유용성

이유경, 김원배, 진소영, 이동화

순천향대학교 의과대학 임상병리학교실

Availability of CD34 Monoclonal Antibody in Chronic Myelogenous Leukemia

You Kyoung Lee, Won Bae Kim, So Young Jin, Dong Wha Lee

Department of Clinical Pathology, College of Medicine, Soonchunhyang University, Seoul, Korea

Abstract

Background: In general, chronic myelogenous leukemia(CML) are classified according to the criteria established by the International Bone Marrow Transplant Registry. However, when a marrow aspirate cannot be obtained because of myelofibrosis or other causes, bone marrow biopsy specimens can be used to provide diagnostic information. As compared with the marrow aspirate, the assessment of the blasts is a major difficulty with biopsy specimen. Anti-CD34 is a monoclonal antibody that reacts with leukemic blasts and bone marrow progenitor cells, immunohistochemical staining for CD34 can be used to classify three phases of CML when the aspirates of bone marrow is inadequate.
Methods: The authors studied 38 bone marrow biopsy specimens, it were diagnosed as CML, representing three phases of disease(chronic, accelerated, and blastic crisis).
Immunohistochemical staining for CD34 was performed using CD34 monoclonal antibody in paraffinembedded tissue. We assess a correlation between the clinical phases of CML
and the proportion of CD34 positive cells.
Results: The proportion of CD34 positive cells among chronic, accelerated, blastic phases, and indeterminate group of CML were 4.3(1.7∼9.0)%, 10.1(7.4∼12.7)%, 31.2(10.2∼87.3)%, and 13.35(8.7∼20.0)%, respectively. The differences in CD34 positivity between various phases of CML were highly significant(P=0.0001). We classified CML according to bone marrow histology; granulocytic types and granulocytic/megakaryocytic(mixed) type. The differences in CD34 positivity among histologic types were significant high
proportion of CD34 positive cells(P=0.0191) in granulocytic type of blastic phase.
Conclusion: This study demonstrated that CD34 immunohistochemical staining represents a reliable method for classifying CML in cases in where a bone marrow
aspirate is not available, and further studies are needed in order to find out the relationship between a degree of CD34 positivity and histologic classification.

Keywords Chronic myelogenous leukemia; CD34 monoclonal antibody; Histologic classification; Granulocytic type; Mixed type;

Article

Korean J Hematol 1997; 32(1): 98-105

Published online March 31, 1997

Copyright © The Korean Society of Hematology.

만성 골수성 백혈병에서의 CD34 단클론항체 염색의 유용성

이유경, 김원배, 진소영, 이동화

순천향대학교 의과대학 임상병리학교실

Availability of CD34 Monoclonal Antibody in Chronic Myelogenous Leukemia

You Kyoung Lee, Won Bae Kim, So Young Jin, Dong Wha Lee

Department of Clinical Pathology, College of Medicine, Soonchunhyang University, Seoul, Korea

Abstract

Background: In general, chronic myelogenous leukemia(CML) are classified according to the criteria established by the International Bone Marrow Transplant Registry. However, when a marrow aspirate cannot be obtained because of myelofibrosis or other causes, bone marrow biopsy specimens can be used to provide diagnostic information. As compared with the marrow aspirate, the assessment of the blasts is a major difficulty with biopsy specimen. Anti-CD34 is a monoclonal antibody that reacts with leukemic blasts and bone marrow progenitor cells, immunohistochemical staining for CD34 can be used to classify three phases of CML when the aspirates of bone marrow is inadequate.
Methods: The authors studied 38 bone marrow biopsy specimens, it were diagnosed as CML, representing three phases of disease(chronic, accelerated, and blastic crisis).
Immunohistochemical staining for CD34 was performed using CD34 monoclonal antibody in paraffinembedded tissue. We assess a correlation between the clinical phases of CML
and the proportion of CD34 positive cells.
Results: The proportion of CD34 positive cells among chronic, accelerated, blastic phases, and indeterminate group of CML were 4.3(1.7∼9.0)%, 10.1(7.4∼12.7)%, 31.2(10.2∼87.3)%, and 13.35(8.7∼20.0)%, respectively. The differences in CD34 positivity between various phases of CML were highly significant(P=0.0001). We classified CML according to bone marrow histology; granulocytic types and granulocytic/megakaryocytic(mixed) type. The differences in CD34 positivity among histologic types were significant high
proportion of CD34 positive cells(P=0.0191) in granulocytic type of blastic phase.
Conclusion: This study demonstrated that CD34 immunohistochemical staining represents a reliable method for classifying CML in cases in where a bone marrow
aspirate is not available, and further studies are needed in order to find out the relationship between a degree of CD34 positivity and histologic classification.

Keywords: Chronic myelogenous leukemia, CD34 monoclonal antibody, Histologic classification, Granulocytic type, Mixed type,

Blood Res
Volume 59 2024

Stats or Metrics

Share this article on

  • line

Blood Research

pISSN 2287-979X
eISSN 2288-0011
qr-code Download